JP2015524432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015524432A5 JP2015524432A5 JP2015524242A JP2015524242A JP2015524432A5 JP 2015524432 A5 JP2015524432 A5 JP 2015524432A5 JP 2015524242 A JP2015524242 A JP 2015524242A JP 2015524242 A JP2015524242 A JP 2015524242A JP 2015524432 A5 JP2015524432 A5 JP 2015524432A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- apolipoprotein
- protein
- biologically active
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261675549P | 2012-07-25 | 2012-07-25 | |
| US61/675,549 | 2012-07-25 | ||
| PCT/US2012/066334 WO2014018079A1 (en) | 2012-07-25 | 2012-11-21 | Method of treating hyperglycemic disorders using apoliprotein aiv |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015524432A JP2015524432A (ja) | 2015-08-24 |
| JP2015524432A5 true JP2015524432A5 (cg-RX-API-DMAC7.html) | 2016-01-21 |
| JP6033433B2 JP6033433B2 (ja) | 2016-11-30 |
Family
ID=47295208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015524242A Expired - Fee Related JP6033433B2 (ja) | 2012-07-25 | 2012-11-21 | アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10232019B2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6033433B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012385960B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2878684A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014018079A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012100010A1 (en) | 2011-01-19 | 2012-07-26 | University Of Cincinnati | Apolipoprotein aiv as an antidiabetic peptide |
| WO2013109342A1 (en) | 2012-01-19 | 2013-07-25 | University Of Cincinnati | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
| JP2015524808A (ja) | 2012-07-25 | 2015-08-27 | ユニバーシティ・オブ・シンシナティ | アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| FR2686605B1 (fr) | 1992-01-27 | 1994-03-11 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides, leur preparation et leur utilisation. |
| AU7242394A (en) | 1993-05-28 | 1994-12-20 | Merck & Co., Inc. | Method to control appetite and treat obesity |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| NZ537006A (en) | 2002-05-17 | 2008-01-31 | Esperion Therapeutics Inc | The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ |
| US20100267052A1 (en) | 2006-09-01 | 2010-10-21 | American Type Culture Collection | Compositions and methods for diagnosis and treatment of type 2 diabetes |
| EP2257814B1 (en) | 2008-03-21 | 2012-08-29 | Podiceps B.v. | Diagnostic of pre-symptomatic metabolic syndrome |
| CN101747305B (zh) | 2008-11-28 | 2014-06-18 | 中国医学科学院药物研究所 | 硝克柳胺化合物晶v型、其制法和其药物组合物与用途 |
| WO2012100010A1 (en) * | 2011-01-19 | 2012-07-26 | University Of Cincinnati | Apolipoprotein aiv as an antidiabetic peptide |
| WO2013109342A1 (en) | 2012-01-19 | 2013-07-25 | University Of Cincinnati | Method of treating diabetes using non-glycosylated apolipoprotein a-iv |
| WO2014011908A1 (en) * | 2012-07-11 | 2014-01-16 | Esperion Therapeutics, Inc. | Apolipoprotein mixtures |
| JP2015524808A (ja) | 2012-07-25 | 2015-08-27 | ユニバーシティ・オブ・シンシナティ | アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法 |
-
2012
- 2012-11-21 JP JP2015524242A patent/JP6033433B2/ja not_active Expired - Fee Related
- 2012-11-21 AU AU2012385960A patent/AU2012385960B2/en not_active Ceased
- 2012-11-21 US US14/416,541 patent/US10232019B2/en active Active
- 2012-11-21 WO PCT/US2012/066334 patent/WO2014018079A1/en not_active Ceased
- 2012-11-21 CA CA2878684A patent/CA2878684A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cahn et al. | New forms of insulin and insulin therapies for the treatment of type 2 diabetes | |
| Home | The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequences | |
| JP2014526441A5 (cg-RX-API-DMAC7.html) | ||
| JP5552046B2 (ja) | インスリン誘導体を含有する薬学的製剤 | |
| EP2611458B1 (en) | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 | |
| US7485620B2 (en) | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof | |
| JP2014501762A5 (cg-RX-API-DMAC7.html) | ||
| US20080213288A1 (en) | Combined Use Of A Modulator Of CD3 And A GLP-1 Compound | |
| RU2013133803A (ru) | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп | |
| EP1515749B1 (en) | Combined use of a modulator of cd3 and a glp-1 compound | |
| JP2018504111A (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| JP2016512205A5 (cg-RX-API-DMAC7.html) | ||
| JP2010514694A5 (cg-RX-API-DMAC7.html) | ||
| EP3268029B1 (en) | Treatment of type 2 diabetes mellitus patients | |
| JP2014513952A5 (cg-RX-API-DMAC7.html) | ||
| JP2012509283A5 (cg-RX-API-DMAC7.html) | ||
| JP2016516016A5 (cg-RX-API-DMAC7.html) | ||
| JP6889154B2 (ja) | グルカゴン類似ペプチド−１受容体亢進剤を含む筋減少症治療用薬学組成物 | |
| Garg | New insulin analogues | |
| JP2020502150A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502151A5 (cg-RX-API-DMAC7.html) | ||
| JP2014504601A5 (cg-RX-API-DMAC7.html) | ||
| JP2015524432A5 (cg-RX-API-DMAC7.html) | ||
| JP2020502056A5 (cg-RX-API-DMAC7.html) | ||
| JP2022060514A (ja) | ガバペンチノイドからの干渉が減少し、ｈｇｆ異型体を発現するｄｎａコンストラクトを用いる神経病症の治療 |